COMPARATIVE EVALUATION OF STAINLESS STEEL STENT (SIROLIMUS) AND COBALT CHROMIUM STENT (SIROLIMUS) IN PATIENT WITH CORONARY ARTERY DISEASE
Abstract
Coronary Artery Disease (CAD) occurs when the arteries of the heart that normally provide blood and oxygen to the heart are narrowed or even completely blocked due to clot formation. The Stenting implantation composes 84.2% of all Percutaneous coronary intervention (PCI). Despite the widespread use of these devices, bare metal stents (BMS) have been associated with a 20-30% restenosis rate which requires reintervention. In December 2006, US Food and Drug Administration cardiovascular experts concluded that for many patients, such as those with uncomplicated medical histories who undergo elective stenting of simple coronary blockages, drug-eluting stents remain a safe and appropriate therapy. Previously reports are suggestive of similar clinical outcomes for stainless steel and cobalt chromium bare metal stent. No reports are available for comparison of sirolimus eluting stainless steel stent and sirolimus eluting cobalt chromium stent. The present study was undertaken with the objective of comparative evaluation of Stainless Steel Stent (Sirolimus) and Cobalt Chromium Stent (Sirolimus) in Patient with Coronary Artery Disease. A single centric, retrospective, non-randomized study involving 118 patients who have undergone PCI from January 2011 to March 2012 implanted with either Sirolimus Stainless Steel Stent (SSSS) or Sirolimus Cobalt Chromium Stents (SCCS) were included in the study. Primary objective was to determine and compare the clinical outcome and rates of target vessel revascularization (TVR) in patients undergoing primary PCI for CAD patients who were treated with Sirolimus cobalt-chromium stents and Sirolimus stainless steel stents. The secondary outcomes of study were Major Adverse Cardiac Events, mortality at the end of 1 month, 6 month and 1 year of outcomes. At 1 month follow up there was no significant difference between two groups (p = 0.96). The individual clinical component showed no difference in occurrence of death (p = 0.29), MI (p = 0.29) and TLR (p = 0.96) at end of 6 month. The cumulative clinical outcome at 1 year rate of target vessel revascularization TVR (SSSS 1.75% versus SCCS 0%, p = 0.29), target lesion revascularization (SSSS 5.27% versus SCCS 1.63%, p = 0.27), and Major Adverse Cardiac Events (SSSS 22.80% versus SCCS 13.11%, p = 0.16). This study showed that among Coronary artery disease (CAD) patients undergoing primary percutaneous coronary intervention, sirolimus stainless steel stent showed similar efficacy and safety to sirolimus cobalt chromium stent.
Keywords:
Target Vessel Revascularization, Target Lesion Revascularization, Major Adverse Cardiac Events, RestenosisDOI
https://doi.org/10.25004/IJPSDR.2016.080402References
2. Moliterno DJ. Healing Achilles—sirolimus versus paclitaxel. N Engl J Med 2005; 353:724-6.
3. Arjomand H, Turi ZG, McCormick D, Goldberg S. Percutaneous coronary intervention: historical perspectives, current status, and future direction. Am Heart J 2003; 146:787-96.
4. Gawaz M, Neumann FJ, Ott I, May A, Schömig A. May A, Rudiger S, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94:279-85.
5. Caramori PR, Lima VC, Seidelin PH, Newton GE, Parker JD, Adelman AG. Long-term endothelial dysfunction after coronary stenting. J Am Coll Cardiol 1999; 34:1675-9.
6. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2002; 105:1257-67.
7. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F, Lotrionte M. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a meta-analysis of randomized bare-metal-stent-controlled trials. Int J Cardiol 2005; 100:119-23.
8. Hill RA, Dündar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004; 25:902-19.
9. Koh AS, Choi LM, Sim LL, Tan JW, Khin LW, Chua TS. Comparing the use of cobalt chromium stents to stainless steel stents in primary percutaneous coronary intervention for acute myocardial infarction: a prospective registry. Acute cardiac care 2011; 13(4):219-22.
10. Moreno R, Sanchez A, Galeote G, Calvo L, Martin R, Jimenez S. Periprocedural (30-day) risk of myocardial infarction after drug-eluting coronary stent implantation: a meta-analysis comparing cobalt-chromium and stainless steel drug-eluting coronary stents. EuroIntervention, 2011;6(8):1003-10.
11. Jens H, Frank MB, Robert HG, Hans W. Compliance of a cobalt chromium coronary stent alloy. Current Controlled Trials in Cardiovascular Medicine, 2005; 6:17.
12. Milewski K, Pajak J, Ewa ZP, LIiszka L, Piotr PB, Zurakowski A. Comparison of thin-strut cobalt-chromium stents and stainless steel stents in a porcine model of neointimal hyperplasia. Med Science Monitoring. 2010; 16(1): BR40-4.
13. Hansi C, Alexander R, Ingo A, Christoph B, Christoph H, Arab A. Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces. Catheter Cardiovascular Intervention. 2009; 73(4):488-96.
14. Xiang D, Yunjun R, Zhihua G, Hong C, Qui J, Yi S. Comparison of angiographic and IVUS follow-up between the two different drug-eluting stents implanted simultaneously in the same individuals. Journal of Invasive Cardiology. 2012; 24(8):374-8.
15. Kimura T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Morimoto T. Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial. Circulation. 2012; 126(10):1225-1236.
16. Naito R, Wada H, Funayama H, Sugawara Y, Kubo N, Sakakura K. Comparison of long-term clinical outcomes between sirolimus-eluting stents and paclitaxel-eluting stents following rotational atherectomy. International Heart Journal. 2012; 53(3):149-53.
17. He Y, Mitnz GS, Bharaj H, Castellanos C, Wu X, Maehara A. Intravascular ultrasound assessment of cobalt chromium versus stainless steel drug-eluting stent expansion. American Journal Cardiology. 2010; 105(9):1272-5.
18. Henrique BR, Carlos a, Augusto C Lopes JR, Rodrigo B, Luiz JK. “Stainless steel versus cobalt-chromium bare metal stents: clinical impact of the metal alloy in a "real world" scenario”, Revista Brasileira de Cardiologia Invasiva, 2011; 19(1):47-52.
19. Scott NA, Nunes GL, Thomas CN, Viel K, Harker LA, Robinson KA. Comparison of the thrombogenicity of stainless steel and tantalum coronary stents. American Heart Journal. 1995; 129(5):866-72.
20. Haase J, Storger H. Comparison of stainless steel stents coated with turbostratic carbon and uncoated stents for percutaneous coronary interventions. Journal of Invasive Cardiology. 2003; 15(10):562-5.
Published
Abstract Display: 315 
PDF Downloads: 467 How to Cite
Issue
Section
Copyright (c) 2016 J. S. Shah, J. B. Patel, S. Dani
This work is licensed under a Creative Commons Attribution 4.0 International License.
